🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareWeekly check-in thread — March 10–16, 2026

Weekly check-in thread — March 10–16, 2026

mike_mod Sun, May 31, 2026 at 8:46 PM 7 replies 337 viewsPage 1 of 2
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
May 31, 2026 at 8:46 PM#1

Counting rather than debating, for once. The debate can happen underneath.

I keep finding that the number in the press summary and the number in the paper are not the same number, and the difference is always in the same direction.

What would genuinely help is knowing how to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases.

Roughly, people seem to land in one of these:

  • Held where they were and waited it out
  • Changed one variable and kept everything else fixed
  • Changed several things at once and cannot now attribute the result
  • Stopped and reassessed from a clean baseline

Say which and say why — the why is the useful half.

42 12PharmHunterJen, TomTeleRx, DoseLogDan and 39 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
May 31, 2026 at 9:12 PM#2

Taking the question as asked, rather than the general version of it. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.

I would rather be corrected than agreed with, if it comes to it.

Last edited: Jun 1, 2026 at 3:12 AM
41 11PharmacoVig_BOS, SurmountFan_IN, PeptideChemSF and 38 others
Reply Quote Save Share Report
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
May 31, 2026 at 9:38 PM#3
Dr.ObesityMed said:
Relative and absolute effects need reading together.

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 25,000 GLP-1 users vs matched controls showed reduced all-cause mortality (HR 0.81) over 5 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
Last edited: Jun 1, 2026 at 2:38 AM
40 10AttorneyGrant, DebRD_ATL, KristenIndy and 37 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
TinaHashiRN
Member
345
1,567
Sep 2024
Raleigh, NC
May 31, 2026 at 10:04 PM#4
mike_mod said:
I keep finding that the number in the press summary and the number in the paper are not the same number, and the difference is always in the same…

This matches mine closely enough to be worth saying so. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

Correct me if the detail matters more than I have assumed.

Last edited: Jun 1, 2026 at 4:04 AM
39 9Admin, Dr.Martinez, mike_mod and 36 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Jun 1, 2026 at 12:27 AM#5

Clinical perspective, offered as context rather than as advice.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

38 8FranDenver, Dr.BariatricHTX, LindaRN_retired and 35 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register